Dian Xia, Kun Liu, Xin Wang, SongBai Yan, Qi Liu, Liangkuan Bi
Department of Urology, Second Hospital of Anhui Medical University.
Department of Oncology, First Hospital of Anhui Medical University, Hefei, China.
Anticancer Drugs. 2022 Nov 1;33(10):1156-1162. doi: 10.1097/CAD.0000000000001352. Epub 2022 Aug 9.
Bladder cancer is the most common malignancy in the urinary system, and muscle-invasive bladder cancer (MIBC) accounts for 25-30% among all types of bladder cancers. Although MIBC can be treated by surgery and chemotherapy, favorable outcomes can still not be obtained. In recent years, the emergence of immunotherapy represented by programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors and other immune checkpoint inhibitors provides attractive prospects for the treatment of advanced bladder cancer. PD-1/PD-L1 inhibitors can block the binding of PD-1/PD-L1, which can block negative immunomodulatory signals, thereby improving anti-tumor immune activity. In this article, we reported a case of advanced MIBC who achieved complete pathological remission after receiving the combined therapy of toripalimab and chemotherapy, which could provide clinical data for the treatment of bladder cancer with triprizumab.
膀胱癌是泌尿系统中最常见的恶性肿瘤，肌肉浸润性膀胱癌（MIBC）在所有类型的膀胱癌中占25%-30%。尽管MIBC可通过手术和化疗进行治疗，但仍无法获得理想的治疗效果。近年来，以程序性死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）抑制剂等免疫检查点抑制剂为代表的免疫疗法的出现，为晚期膀胱癌的治疗提供了诱人的前景。PD-1/PD-L1抑制剂可阻断PD-1/PD-L1的结合，从而阻断负性免疫调节信号，进而提高抗肿瘤免疫活性。在本文中，我们报告了1例晚期MIBC患者，该患者在接受托瑞帕利单抗联合化疗后实现了完全病理缓解，可为替雷利珠单抗治疗膀胱癌提供临床数据。
